Trial Profile
Pilot Study of Crenolanib Combined With Standard Salvage Chmetherapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Dec 2023
Price :
$35
*
At a glance
- Drugs Crenolanib (Primary) ; Cytarabine; Etoposide; Fludarabine; Granulocyte colony-stimulating factors; Idarubicin; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors AROG Pharmaceuticals
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association
- 28 Feb 2018 Status changed from active, no longer recruiting to completed.
- 16 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 May 2018.